Hepatotoxicity from pyrazinamide based anti-tuberculous therapy: protective effect from isoniozid and HIV infection?

Kedda, M-a.; Lose, F.; Dully, D.; Bell, E.; Thompson, P. J.; Uphom, J.
March 2005
Thorax;Mar2005, Vol. 60 Issue 3, p210
Academic Journal
The article informs that in 1999 the American Thoracic Society, the Centers for Disease Control and Prevention, and the Infectious Diseases Society of America endorsed a two month daily regimen of rifampin and pyrazinamide (2RZ) for the treatment of latent tuberculosis infection. This recommendation followed a prospective randomized trial in HIV infected persons showing that 2RZ had similar efficacy and safety to a 12 month regimen of daily isoniazid (12H). These two papers examine the incidence of 2RZ related hepatotoxicity.


Related Articles

  • Rifampicin.  // Reactions Weekly;Nov2015, Vol. 1576 Issue 1, p221 

    The article presents a case study of 69 solid organ recipients with tuberculosis identified a patient who developed hepatotoxicity during treatment with rifampicin 900 mg/day.

  • Retraction.  // Sexually Transmitted Infections;Aug2014, Vol. 90 Issue 5, p407 

    A correction to the article "P3.336 Seroprevalence of Human Immunodeficiency Virus (HIV) Infection Amongst Tuberculosis (TB) Patients Attending TB/DOTS Centre in Nnewi South East Nigeria" that was published in a 2013 issue is presented.

  • Vitamin D Status among Pulmonary TB Patients and Non-TB Controls: A Cross-Sectional Study from Mwanza, Tanzania. Friis, Henrik; Range, Nyagosya; Changalucha, John; PrayGod, George; Jeremiah, Kidola; Faurholt-Jepsen, Daniel; Krarup, Henrik; Mølgaard, Christian; Andersen, Åse Bengaard // PLoS ONE;Dec2013, Vol. 8 Issue 12, p1 

    Background: Little is known about vitamin D status in low-income populations burdened with infectious diseases. Hence, there is a need for data on correlates of serum 25-hydroxy vitamin D (S-25(OH)D) and its validity during infections. Objective: To assess the role of pulmonary TB (PTB) and HIV...

  • DNA restriction fragment length polymorphism analysis of Mycobacterium tuberculosis isolates from HIV-seropositive and HIV-seronegative patients in Kampala, Uganda. Asiimwe, Benon B.; Joloba, Moses L.; Ghebremichael, Solomon; Koivula, Tuija; Kateete, David P.; Katabazi, Fred A.; Pennhag, Alexander; Petersson, Ramona; Kallenius, Gunilla // BMC Infectious Diseases;2009, Vol. 9 Issue 1, Special section p1 

    Background: The identification and differentiation of strains of Mycobacterium tuberculosis by DNA fingerprinting has provided a better understanding of the epidemiology and tracing the transmission of tuberculosis. We set out to determine if there was a relationship between the risk of...

  • Tuberculosis Drug Resistance and HIV Infection, the Netherlands. Haar, Catharina Hendrika; Cobelens, Frank G. J.; Kalisvaart, Nico A.; Van der Have, Jan J.; Van Gerven, Paul J. H. J.; Van Soolingen, Dick // Emerging Infectious Diseases;May2007, Vol. 13 Issue 5, p776 

    In the Netherlands during 1993-2001, multidrug-resistant tuberculosis among newly diagnosed patients was more frequent in those with HIV coinfection (5/308, 1.6%) than in those with no HIV infection (39/646, 0.6%; adjusted odds ratio 3.43, p = 0.015). Four of the 5 patients coinfected with...

  • Testing for HIV among patients with tuberculosis in Montreal. Geduld, Jennifer; Brassard, Paul; Culman, Kate; Tannenbaum, Terry Nan // Clinical & Investigative Medicine;Jun99, Vol. 22 Issue 3, p111 

    Provides information on a study which determined the rate of HIV testing among patients with tuberculosis (TB) in Montreal. Characteristics of patients with TB tested for HIV infection; Factors associated with HIV testing; Rate of HIV seropositivity.

  • The Changing Natural History of Tuberculosis and HIV Coinfection in an Urban Area of Hyperendemicity. Bekker, Linda-Gail; Wood, Robin // Clinical Infectious Diseases;May2010 Supplement 3, Vol. 50, pS208 

    Tuberculosis (TB) has proven to be difficult to control in regions with a high prevalence of human immunodeficiency virus (HIV) infection. We previously described high prevalence of HIV infection among adults (23%) and rapidly escalating TB notification rates in a peri-urban township, Site-M in...

  • Hepatoxicity Alert: Rifampin and Pyrazinamide as Treatment for Latent Tuberculous Infection.  // American Jails;Jan/Feb2004, Vol. 17 Issue 6, p67 

    Focuses on the use of rifampin and pyrazinamide as treatment for latent tuberculosis infection. Hepatotoxic effects of rifampin and pyrazinamide; Discussion of a case of an inmate.

  • HIV spike. Vogel, Lauren // CMAJ: Canadian Medical Association Journal;9/20/2011, Vol. 183 Issue 13, pE1011 

    The article focuses on a communicable disease report by the city health board in Ottawa, Ontario on August 10, 2011, which found that HIV cases in the city in 2011 have increased up to 50% compared in 2010.


Read the Article


Sign out of this library

Other Topics